
|Videos|October 17, 2014
Combining Targeted Agents for the Treatment of Lung Cancer
Author(s)Heather Wakelee, MD
Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses the need to combine agents for the treatment of lung cancer.
Advertisement
Clinical Pearls
Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses the need to combine agents for the treatment of lung cancer.
- It is widely believed that 1 molecularly-targeted agent will not be able to cure lung cancer.
- Long term responses have been observed with 1 targeted agent.
- Research needs to be conducted regarding which combinations of agents will be most beneficial or curative.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5







































